Tesamorelin Dosage and Protocols
Tesamorelin dosage protocols reported in published research, plus reconstitution and storage.
Dosing Summary
Dosing details above reflect FDA-approved labeling and/or published clinical protocols. Always refer to the official drug label (linked above) for approved prescribing details, contraindications, and warnings.
Reported protocol doses
Standard dose1–2 mg
Frequency1x daily
Routessubcutaneous
Reconstitution
A 5mg vial with 2.5mL of bacteriostatic water is the pairing reported most often. 5mg vial + 2.5mL bacteriostatic water = 2mg/mL. A 1mg dose is 0.5mL (50 units).
Work out your own concentration with the reconstitution calculator.
Doses shown are those reported in published research, not a recommendation.
References
- Effects of tesamorelin on visceral fat in HIV-associated lipodystrophy
- Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine. 2007;357(23):2359-2370.
- Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV.
- FDA prescribing information
- Falutz J, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat. Journal of Clinical Endocrinology & Metabolism. 2010;95(9):4291-4304.
- Predictors of Treatment Response to Tesamorelin, a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat.